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Abstract
Background: Heat shock protein (HSP) 47, a collagen-specific molecular chaperone, is involved
in the processing and/or secretion of procollagens, and its expression is increased in various fibrotic
diseases. The aim of this study was to determine whether quantitative immunohistochemical
evaluation of the expression levels of HSP47, type I procollagen and α-smooth muscle actin (SMA)
allows the differentiation of idiopathic usual interstitial pneumonia (UIP) from UIP associated with
collagen vascular disease (CVD) and idiopathic nonspecific interstitial pneumonia (NSIP).
Methods: We reviewed surgical lung biopsy specimens of 19 patients with idiopathic UIP, 7 with
CVD-associated UIP and 16 with idiopathic NSIP and assigned a score for the expression of HSP47,
type I procollagen and α-SMA in type II pneumocytes and/or lung fibroblasts (score 0 = no; 1 =
weak; 2 = moderate; 3 = strong staining).
Results: The expression level of HSP47 in type II pneumocytes of idiopathic UIP was significantly
higher than in CVD-associated UIP and idiopathic NSIP. The expression of HSP47 in fibroblasts was
significantly higher in idiopathic UIP and idiopathic NSIP than in CVD-associated UIP. The
expression of type I procollagen in type II pneumocytes was significantly higher in idiopathic UIP
than in idiopathic NSIP. The expression of type I procollagen in fibroblasts was not different in the
three groups, while the expression of α-SMA in fibroblasts was significantly higher in idiopathic UIP
than in idiopathic NSIP.
Conclusion: Our results suggest the existence of different fibrotic pathways among these groups
involved in the expression of HSP47 and type I procollagen.
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Background
Heat shock protein (HSP) 47 is a collagen-binding, stress-
inducible protein localized in the endoplasmic reticulum
and is never released into the extracellular matrix. HSP47
plays a specific role in the intracellular processing of pro-
collagen production as a collagen-specific molecular
chaperone [1-4]. HSP47 expression has been shown to be
upregulated in experimental animal models of fibrosis,
including murine bleomycin-induced pulmonary fibrosis
[5,6], rat peritoneal sclerosis [7] and carbon tetrachloride-
induced rat liver cirrhosis [8]. In addition, we previously
reported increased expression of human HSP47 in the
fibrotic lesions of idiopathic pulmonary fibrosis (IPF) [9],
fibrotic transplanted kidney [10], and peritoneal sclerosis
[11]. Recent reports have demonstrated that HSP47
expression is highly tissue- and cell-specific, and is
restricted to most phenotypically altered collagen-produc-
ing cells, and correlates well with that of collagen [9-11].
These findings suggest the important role of HSP47 in col-
lagen synthesis in various fibrotic disorders. Furthermore,
it was demonstrated that inhibition of HSP47 by anti-
sense oligodeoxynucleotides markedly suppressed the
production of collagen in 3T6 cells [4], in experimental
proliferative glomerulonephritis [12] and in experimental
peritoneal fibrosis [7]. These findings suggest that HSP47
might be a promising target for the treatment of fibrotic
diseases.
Increased numbers of myofibroblasts in pulmonary fibro-
sis has been documented in both human lung tissues and
those of animal models [5,6,13,14]. Myofibroblasts par-
ticipate in remodeling and progressive destruction of the
lung parenchyma through several mechanisms including
increased extracellular matrix synthesis and contractility
of the lung parenchyma [15]. We also showed previously
that bleomycin treatment induced a marked increase in
myofibroblasts in the active fibrotic areas of the lung from
the early fibrotic stage in mice [5,6]. Activation of alpha-
smooth muscle actin (α-SMA)-positive myofibroblasts is
believed to play a key role in the progression of pulmo-
nary fibrosis.
Patients with usual interstitial pneumonia (UIP) associ-
ated with a collagen vascular disease (CVD) have an
improved prognosis compared with patients with idio-
pathic UIP [16]. Therefore, whether CVD-associated UIP
and idiopathic UIP are the same pathological entity
remains unresolved. Although identifying the pattern of
UIP on surgical lung biopsy provides important prognos-
tic data in distinction from other patterns of interstitial
pneumonia [17-19], there are few studies that analyzed
the individual histopathologic features comprising this
pattern [20]. Although Flaherty et al [16] recently reported
that patients with CVD-associated UIP have fewer fibrob-
lastic foci in the lung and better prognosis than those with
idiopathic UIP, the phenotypic difference of lung cells
(e.g., fibroblasts and alveolar epithelial cells) between
these two diseases and its association with the prognosis
are poorly understood.
The recognition that lung biopsy samples of some
patients with idiopathic interstitial disease do not fit into
any well-defined histopathologic patterns of idiopathic
interstitial pneumonia led to the proposal of the terms
"unclassified interstitial pneumonia" by Kitaichi in 1990
[21] and nonspecific interstitial pneumonia (NSIP) by
Katzenstein and Fiorelli in 1994 [22]. NSIP is character-
ized by varying degrees of inflammation and fibrosis
within the alveolar walls. However, the most distinctive
feature of NSIP is the temporal uniformity, which is in
sharp contrast to the temporal heterogeneity seen in UIP.
Among idiopathic interstitial pneumonias, NSIP has a
more favorable response to corticosteroids and a better
prognosis than UIP [17-19,23,24]. Based on these studies,
NSIP is currently accepted as a clinicopathological entity
in idiopathic interstitial pneumonias. Based on this back-
ground, we speculated that the pathogenesis of NSIP is
different from UIP. In this regard, the phenotypic differ-
ence in fibroblasts and epithelial cells between these dis-
eases is also not well elucidated.
The main hypothesis of the present study was that the
expression levels of HSP47 in alveolar epithelial cells and
lung fibroblasts are different in idiopathic UIP, CVD-asso-
ciated UIP and idiopathic NSIP, thus allowing differentia-
tion of these conditions. To test our hypothesis, we
determined the expression levels of HSP47, type I procol-
lagen and α-SMA in fibroblasts and type II pneumocytes
in surgical lung biopsy specimens by
immunohistochemistry.
Materials and methods
Study populations
The subjects of this study were patients enrolled in the
hospitals of Nagasaki University School of Medicine. The
study protocol was approved by the institutional review
board, and informed consent was obtained from each
patient. They included 19 patients with idiopathic UIP, 7
with CVD-associated UIP and 16 with idiopathic NSIP.
Patients with idiopathic UIP and idiopathic NSIP had nei-
ther shown any signs nor positive serological and other
markers of CVD. The associated diagnosis in the CVD-
associated UIP patients were systemic sclerosis (n = 3),
systemic sclerosis with Sjögren syndrome (n = 1), polymy-
ositis with Sjögren syndrome (n = 1), primary Sjögren syn-
drome (n = 1) and mixed connective tissue disease (n = 1).
Idiopathic NSIP patients included 8 with cellular and
fibrosing pattern and 8 with fibrosing pattern. None of
these patients had received steroids or other immunosup-
pressants therapy at the time of clinical sample collection.Respiratory Research 2005, 6:57 http://respiratory-research.com/content/6/1/57
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Photomicrographs of histopathological and immunohistochemical studies of representative surgical lung biopsy specimens (A-E;  idiopathic UIP, F-J; CVD-associated UIP, K-O; idiopathic NSIP, scale bar = 100 µm) Figure 1
Photomicrographs of histopathological and immunohistochemical studies of representative surgical lung biopsy specimens (A-E; 
idiopathic UIP, F-J; CVD-associated UIP, K-O; idiopathic NSIP, scale bar = 100 µm). Histopathological examination (hematoxy-
lin-eosin staining) revealed fibroblastic foci in both idiopathic UIP (A) and CVD-associated UIP (F), and fibroblast proliferation 
in idiopathic NSIP (K). Hyperplastic cuboidal epithelial cells were stained with cytokeratin, indicating that these cells were type 
II pneumocytes (B, G and L). Strong expression of HSP47 was noted predominantly in fibroblasts and type II pneumocytes in 
idiopathic UIP (C). Weak or no expression of HSP47 was noted in fibroblasts and type II pneumocytes in CVD-associated UIP 
(H). In idiopathic NSIP, strong expression of HSP47 was noted in fibroblasts, but not in type II pneumocytes (M). Type I procol-
lagen was strongly expressed predominantly in fibroblasts and type II pneumocytes in idiopathic UIP (D), but neither in CVD-
associated UIP (I) nor idiopathic NSIP (N). Expression of α-SMA was noted in some of fibroblasts, indicating that these cells 
were myofibroblasts, in all three diseases (E, J and O). Insets c, d, h, i, m and n are pictures taken at high power magnification 
(scale bar = 20 µm) of corresponding C, D, H, I, M and N sections to clearly show the phenotypic difference of type II pneumo-
cytes. α-SMA = α-smooth muscle actin; CVD = collagen vascular disease; HSP47 = heat shock protein 47; NSIP = nonspecific 
interstitial pneumonia; UIP = usual interstitial pneumonia.Respiratory Research 2005, 6:57 http://respiratory-research.com/content/6/1/57
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Patients characteristics before lung biopsy including age,
smoking history, period from the onset to the surgical
lung biopsy, results of pulmonary function tests and arte-
rial blood gas analysis were collected from either the hos-
pital medical records or those of the general practitioners.
In the patients in this study, a suspicion of interstitial
pneumonia was based on symptoms, physiologic abnor-
malities, and HRCT findings. The diagnosis was patholog-
ically confirmed by open lung biopsy or video-assisted
thoracoscopic surgery from multiple lobes in all patients
and classified according to the American Thoracic Society/
European Respiratory Society consensus criteria [25].
Control lung tissues were obtained from normal areas of
lungs surgically removed for lung cancer (11 men and 9
women; median age, 62 years; range, 47 to 81 years).
Antibodies
The primary antibodies used for the immunohistochemi-
cal studies included anti-human procollagen type I
(Chemicon, Temecula, CA), anti-α-SMA (Neomarkers,
Fremont, CA), anti-human cytokeratin (clone MNF116;
Dako Corporation, Carpinteria, CA) and anti-HSP47
(Biotechnologies Corp., Victoria, BC, Canada). α-SMA
and cytokeratin were used as markers of myofibroblasts
and epithelial cells, respectively. Negative control studies
were performed by using irrelevant immunoglobulin G
with the same subclass of the first antibodies instead of
the primary antibodies.
Immunohistochemistry
Immunohistochemistry was performed with the conven-
tional avidin-biotin-peroxidase histochemical technique
using Vecstain Elite ABC Kit (Vector Laboratories, Burlin-
game, CA). Briefly, sequential paraffin sections (4-µm-
thick) were deparaffinized with toluene and rinsed thor-
oughly with ethanol. The sections were then soaked in
0.3% H2O2 with absolute methanol for 20 minutes at
room temperature to inactivate the endogenous peroxi-
dase activity. They were incubated with blocking serum
for 30 minutes, and then covered with primary antibodies
and incubated for 1 hour. After washing in phosphate-
buffered saline (PBS), the sections were processed further
using the kits according to the instructions provided by
the manufacturer, and then developed with 3,3'-diami-
nobenzidine and H2O2, followed by the Mayer's hema-
toxylin staining method.
Pathologic Assessment
The profusion of fibroblastic foci in idiopathic UIP and
CVD-associated UIP was graded semiquantitatively using
a grading system of 0 to 3 (0 = absent; 1 = mild; 2 = mod-
erate; 3 = marked) according to the method described pre-
viously [16]. The staining intensity and distribution of
HSP47, α-SMA and type I procollagen in fibroblasts in
active fibrotic areas (fibroblastic foci in UIP cases; alveolar
septal interstitium expanded by fibrosis and intra-alveolar
organizing fibrosis in NSIP cases) was also scored semi-
quantitatively using a grading system of 0 to 3 (0 = no
staining; 1 = weak staining; 2 = moderate staining; 3 =
Table 1: Patient Characteristics
Idiopathic UIP CVD-associated UIP Idiopathic NSIP p value
Age (years) 64 (34–72) 44 (38–63) 58 (28–75) 0.06
Sex (male/female) 17/2 1/6 5/11 0.0002
Smoking (none/ex/smoke) 6/7/6 5/2/0 10/3/2 0.15
Symptom onset (months) 9 (5–38) 12 (4–35) 6 (1–74) 0.44
Spirometry:
VC (L) 2.63 (1.28–3.81) 2.01 (1.34–2.63) 2.50 (1.11–3.39) 0.10
predicted VC (%) 78.6 (55.8–117.0) 67.8 (53.5–112.3) 79.9 (50.0–108.1) 0.59
FEV1 (L) 2.18 (1.08–2.81) 1.67 (1.13–2.28) 1.72 (0.99–2.98) 0.05
predicted FEV (%) 84.10 (65.5–90.6) 84.3 (78.1–94.6) 80.79 (51.0–96.2) 0.19
Gas exchange:
DLco (ml/min/mmHg) 9.13 (6.5–14.65) 9.94 (3.96–20.27) 11.45 (6.0–19.85) 0.35
predicted DLco (%) 49.00 (37.2–97.3) 43.80 (25.2–61.4) 57.85 (44.7–109.3) 0.05
Lung volume:
predicted TLC (%) 62.45 (45.2–96.7) 79.90 (58.9–107.6) 71.55 (62.9–112.4) 0.04
TLC (L) 3.52 (1.78–5.39) 3.07 (2.0–4.0) 3.83 (1.8–8.8) 0.41
Arterial blood gases:
PaO2 (mmHg) 82.5 (58.3–108.0) 89.2 (40.5–97.5) 83.4 (67.0–92.9) 0.43
Data are median (range).
α-SMA = α-smooth muscle actin; CVD = collagen vascular disease; DLco = diffusing capacity for carbon monoxide; HSP47 = heat shock protein 47; 
NSIP = nonspecific interstitial pneumonia; Symptom onset = period from the onset to the surgical lung biopsy; TLC = total lung capacity; UIP = 
usual interstitial pneumonia; VC = vital capacity.Respiratory Research 2005, 6:57 http://respiratory-research.com/content/6/1/57
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strong staining). The expression levels of HSP47 and type
I procollagen in type II pneumocytes were scored in a sim-
ilar manner. The fibroblastic foci score and immunohisto-
chemical score for each patient was calculated by
averaging the score of each lobe. Histological sections
were assessed independently, twice by each of two observ-
ers who were blind to the groups. The results were repro-
ducible for interobserver and intraobserver variability.
Statistical analysis was applied to representative results of
one observer.
Statistical Analysis
All values were expressed as median (range). Differences
in categorical data between two groups were assessed by
the Fisher's exact probability test for data of two categories
and by chi-square test for those of three or more catego-
ries. Differences in continuous data between two groups
Box-and-whisker plots of HSP47, type I procollagen and α-SMA in patients with idiopathic UIP, CVD-associated UIP and idio- pathic NSIP Figure 2
Box-and-whisker plots of HSP47, type I procollagen and α-SMA in patients with idiopathic UIP, CVD-associated UIP and idio-
pathic NSIP. (A) Patients with idiopathic UIP and idiopathic NSIP (P < 0.05) had a significantly higher expression of HSP47 in 
fibroblasts than those with CVD-associated UIP. (B) Expression of HSP47 in type II pneumocytes of patients with idiopathic 
UIP was significantly higher than that of CVD-associated UIP and idiopathic NSIP. (C) Expression of type I procollagen in type 
II pneumocytes of patients with idiopathic UIP was significantly higher than in idiopathic NSIP. (D) Patients with idiopathic UIP 
had a significantly higher expression of α-SMA in fibroblasts than those with idiopathic NSIP. *P < 0.01, compared with control. 
†P < 0.05, compared with control. The boxes represent the 25th to 75th percentiles, the solid lines within the boxes show the 
median values, the whiskers are the 10th and 90th percentiles, and the points represent outliers. For abbreviations, see Figure 
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were assessed by using the Wilcoxon rank-sum test and
among three groups by the Kruskal-Wallis rank test. In
addition, logistic regression was used to examine the rela-
tionships between the presence/absence of CVD-associ-
ated UIP, idiopathic NSIP and other variables. Statistical
significance was defined by a p value of less than 0.05. Sta-
tistical analyses were carried out using SAS (SAS Institute,
Inc., Cary, NC).
Results
Patient Characteristics
Table 1 shows the characteristics of patients enrolled in
this study. Baseline demographic and physiologic charac-
teristics were similar among the groups, except for sex and
percentage of predicted total lung capacity.
Histopathological and Immunohistochemical Findings
Photomicrographs of histological and immunohisto-
chemical studies of representative surgical lung biopsy
specimens are shown in Figure 1 (A-E; idiopathic UIP, F-J;
CVD-associated UIP, K-O; idiopathic NSIP). Figure 1A–E,
F–J and 1K–O represent sequential sections, respectively.
Histopathological examination revealed fibroblastic foci
in both idiopathic UIP (Fig. 1A) and CVD-associated UIP
(Fig. 1F) and fibroblast proliferation in idiopathic NSIP
(Fig. 1K). In all diseases, distinct aggregates of closely
spaced fibroblasts with little intervening collagen deposi-
tion were seen and hyperplastic alveolar lining cells cov-
ered their luminal surface. Cuboidal epithelial cells were
stained with cytokeratin, indicating that these cells were
type II pneumocytes (Fig. 1B, G and 1L). Strong expres-
sion of HSP47 was noted predominantly in fibroblasts
and most of type II pneumocytes in idiopathic UIP (Fig.
1C). In contrast, weak or no expression of HSP47 was
noted in fibroblasts and type II pneumocytes in CVD-
associated UIP (Fig. 1H). In idiopathic NSIP, strong
expression of HSP47 was noted in fibroblasts, but not in
type II pneumocytes (Fig. 1M). Type I procollagen was
strongly expressed predominantly in fibroblasts and most
of type II pneumocytes in idiopathic UIP (Fig. 1D), but
neither in CVD-associated UIP (Fig. 1I) nor idiopathic
NSIP (Fig. 1N). Expression of α-SMA was noted in some
of fibroblasts in all three diseases, indicating that these
cells were myofibroblasts (Fig. 1E, J and 1O). Negative
control studies using non-specific immunoglobulin-G
revealed no positive cells (data not shown).
Results of Pathologic Assessment
Patients with idiopathic UIP had higher profusion of
fibroblastic foci (median, 2.0 [range, 0.67–3]) than those
with CVD-associated UIP (1.0 [0–2]), albeit non-signifi-
cantly (p = 0.06). Patients with idiopathic UIP (P < 0.01),
CVD-associated UIP (P < 0.05) and idiopathic NSIP (P <
0.01) had a significantly higher expression of HSP47 in
fibroblasts than that in control. Patients with idiopathic
UIP (P < 0.01) and idiopathic NSIP (P < 0.05) had a sig-
nificantly higher expression of HSP47 in fibroblasts than
that in CVD-associated UIP (Fig. 2A). Patients with idio-
pathic UIP (P < 0.01) and idiopathic NSIP (P < 0.01) had
a significantly higher expression of HSP47 in type II pneu-
mocytes than that in control, while there was no signifi-
cant difference between CVD-associated UIP and control.
Expression of HSP47 in type II pneumocytes of patients
with idiopathic UIP was significantly higher than those of
CVD-associated UIP (P < 0.05) and idiopathic NSIP (P <
0.01, Fig. 2B). Patients with idiopathic UIP (P < 0.01) and
idiopathic NSIP (P < 0.05) had a significantly higher
expression of type I procollagen in fibroblasts compared
with control, while there was no significant difference
between CVD-associated UIP and control (1.0 [0–3], 1.0
[0–1.5], 1.0 [0–1.5] and 0.0 [0–1] for idiopathic UIP,
CVD-associated UIP, idiopathic NSIP and control, respec-
Table 2: Univariate Analysis of the Results of Pathologic Assessment.
Predictor Odds Ratio 95% confidence interval p Value
Idiopathic UIP vs CVD-associated UIP
Fibroblastic foci score 3.73 0.94–14.79 0.06
HSP47 in fibroblasts 12.68 1.53–105.19 0.02
HSP47 in type II pneumocytes 3.39 1.10–10.45 0.03
α-SMA in fibroblasts 4.78 0.44–51.27 0.20
type I procollagen in fibroblasts 2.73 0.61–12.23 0.19
type I procollagen in type II pneumocytes 3.43 0.77–15.32 0.11
Idiopathic UIP vs Idiopathic NSIP
HSP47 in fibroblasts 1.91 0.74–4.95 0.17
HSP47 in type II pneumocytes 6.66 1.76–25.15 0.01
α-SMA in fibroblasts 4.46 0.94–21.17 0.06
type I procollagen in fibroblasts 3.60 0.94–13.77 0.06
type I procollagen in type II pneumocytes 6.10 1.43–25.93 0.01
For abbreviations, see Table 1.Respiratory Research 2005, 6:57 http://respiratory-research.com/content/6/1/57
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tively). Patients with idiopathic UIP (P < 0.01), CVD-asso-
ciated UIP (P < 0.05) and idiopathic NSIP (P < 0.01) had
a significantly higher expression of type I procollagen in
type II pneumocytes than that in control (Fig. 2C). There
was no significant difference in the expression of type I
procollagen in fibroblasts among idiopathic UIP, CVD-
associated UIP and idiopathic NSIP, while that in type II
pneumocytes in patients with idiopathic UIP was signifi-
cantly higher than in idiopathic NSIP (P < 0.01, Fig. 2C).
Patients with idiopathic UIP (P < 0.01), CVD-associated
UIP (P < 0.01) and idiopathic NSIP (P < 0.01) had a sig-
nificantly higher expression of α-SMA in fibroblasts than
that in control (Fig. 2D). Patients with idiopathic UIP had
a significantly higher expression of α-SMA in fibroblasts
than those with idiopathic NSIP (P < 0.05, Fig. 2D).
We further examined the differences between groups by
univariate analysis based on the results of the pathological
assessment (Table 2). The expression of HSP47 in fibrob-
lasts was the most discriminative baseline feature for sep-
arating idiopathic UIP from CVD-associated UIP. The
odds ratio of having idiopathic UIP compared with CVD-
associated UIP was 12.68 for a unit increase in the mean
score of the expression of HSP47 in fibroblasts. The
expression of HSP47 in type II pneumocytes was the most
discriminative baseline feature for separating idiopathic
UIP from idiopathic NSIP. The odds ratio of having idio-
pathic UIP compared with idiopathic NSIP was 6.66 for a
unit increase in the mean score of the expression of
HSP47 in type II pneumocytes.
Discussion
It is important to know the cell type(s) that contributes to
lung fibrogenesis. The histopathologic pattern of UIP is
well-characterized, with the cardinal feature being the
patchy distribution of temporally heterogeneous fibrosis,
comprising areas of established fibrosis with adjacent foci
of fibroblastic proliferation, so-called fibroblastic foci.
Recent studies have emphasized the importance of the
fibroblastic focus, a manifestation of ongoing lung injury
in patients with established fibrosis [13,15,26-29]. A
number of investigators have stressed the prognostic value
of quantifying fibroblastic foci in patients with idiopathic
interstitial pneumonia [28,29]. Furthermore, a previous
study showed that patients with CVD-associated UIP have
fewer fibroblastic foci and better prognosis compared to
patients with idiopathic UIP [16]. In idiopathic NSIP,
which exhibits a more favorable response to corticoster-
oids and has a better prognosis than idiopathic UIP [17-
19,23,24], fibroblastic foci with dense fibrosis are incon-
spicuous or absent [25]. Thus, fibroblasts are believed to
play an important role in the progression of chronic pul-
monary fibrosis. However, previous studies did not fully
elucidate the phenotypic differences in fibroblasts among
idiopathic UIP, CVD-associated UIP and idiopathic NSIP.
We identified higher expression of HSP47 in fibroblasts in
patients with idiopathic UIP and idiopathic NSIP com-
pared with CVD-associated UIP. We also showed that
patients with idiopathic UIP had a significantly higher
expression of α-SMA in fibroblasts than those with idio-
pathic NSIP. The differential expression of HSP47 and α-
SMA in fibroblasts suggests that the underlying patho-
genic process of fibrosis in these diseases may be distinctly
different. The results emphasized that the expression of
HSP47 in fibroblasts is the most discriminative features
between idiopathic UIP and CVD-associated UIP, as iden-
tified by logistic regression. These findings imply that the
expression of HSP47 in fibroblasts could also have impor-
tant prognostic implications in interstitial pneumonias.
Our results also emphasized the importance of the pheno-
typic difference of epithelial cells among idiopathic UIP,
CVD-associated UIP and idiopathic NSIP. Type II pneu-
mocytes hyperplasia in areas of inflammation and fibrosis
is commonly seen in both UIP and NSIP [25]. Although
several studies performed in experimental models empha-
sized the importance of the alveolar epithelium in normal
repair [30,31], the prevailing hypothesis regarding the
pathogenesis of interstitial pulmonary fibrosis has been
that the disease is due to a chronic unsolved inflammatory
response, and in this context, the possible role of the epi-
thelium has been largely neglected. However, there is
increasing evidence supporting the notion that epithelial
injury in the absence of ongoing inflammation is suffi-
cient to cause the development of pulmonary fibrosis
[15,30,31] and that alveolar epithelial cells are the pri-
mary source of cytokines and growth factors involved in
fibroblast migration and proliferation [15]. In spite of
these findings, the precise biological link between alveolar
epithelial injury and fibrosis represent a challenging puz-
zle in which several pieces remain to be assembled.
We recently showed in rodent bleomycin-induced pulmo-
nary fibrosis model that type II pneumocytes start to
express HSP47 with the progression of fibrosis [5,6]. The
present study extended this finding by showing that
hyperplastic type II pneumocytes in idiopathic UIP
express both HSP47 and type I procollagen. These find-
ings suggest that increased number of type II pneumocytes
in addition to fibroblasts produce type I procollagen
through the induction of HSP47 and play an important
role in the development of fibrosis. Our study also dem-
onstrates a lower expression of HSP47 and type I procol-
lagen in type II pneumocytes in CVD-associated UIP and
idiopathic NSIP compared with idiopathic UIP. Interest-
ingly, the expression level of HSP47 in type II pneumo-
cytes was much higher in idiopathic UIP than in
idiopathic NSIP, while there was no significant difference
in the expression level of HSP47 in fibroblasts between
them. Furthermore, the expression of type I procollagen inRespiratory Research 2005, 6:57 http://respiratory-research.com/content/6/1/57
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type II pneumocytes was different among idiopathic UIP,
CVD-associated UIP and idiopathic NSIP in spite of the
similar expression level of type I procollagen in fibrob-
lasts. These findings suggest that the phenotypic differ-
ence of type II pneumocytes in interstitial pneumonias is
more important biological feature than that of fibroblasts.
In addition, we previously reported that treatment with
pirfenidone, an anti-fibrotic agent, decreased HSP47-pos-
itive type II pneumocytes in bleomycin-induced pulmo-
nary fibrosis in mice [6]. This finding further suggests that
HSP47-positive type II pneumocytes might be promising
target for therapeutic strategies designed for idiopathic
UIP.
Several lines of evidence suggest that in some forms of tis-
sue fibrosis, an epithelial-mesenchymal transition actively
participates in the local formation of interstitial fibrob-
lasts [32-34]. This process has been particularly studied in
renal fibrosis. According to these findings, epithelial cells
that detach from their basement membrane enter into epi-
thelial-mesenchymal transition, express HSP47 and type I
procollagen and divide as fibroblasts [32-34]. Whether
this process takes place in the lung in IPF or in other forms
of pulmonary fibrosis is largely unknown, but awaits fur-
ther evaluation both in vitro and in vivo. The present find-
ings that type II pneumocytes express HSP47 and type I
procollagen in idiopathic UIP imply that a similar process
could take place in idiopathic UIP. Further studies are
warranted in order to elucidate the precise mechanism(s)
involved in this process.
In this study, we also investigated whether the expression
of HSP47, type I procollagen and α-SMA in fibroblasts
and/or type II pneumocytes correlated with clinical
course. However, no pathologic feature was associated
with survival nor clinical data such as results of pulmo-
nary function tests and arterial blood gas analysis (data
not shown). This is probably because only small number
of patients was assessed in this study. Further studies of a
large number of patients are required.
Conclusion
In summary, we have shown that type II pneumocytes
and/or lung fibroblasts of patients with idiopathic UIP,
CVD-associated UIP and idiopathic NSIP express different
levels of HSP47 and type I procollagen. Our findings sup-
port the concept that these diseases are different patho-
physiological entities with different fibrotic pathways. We
speculate that careful immunohistochemical evaluation
of HSP47, α-SMA and type I procollagen in the lung may
be a useful method to understand differences in the
underlying pathogenic mechanisms of these diseases. Fur-
ther studies of a large number of patients are required to
determine the prognostic and therapeutic values of
HSP47 expression.
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